Purpose: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus in adults, as adjunct to diet and exercise to improve glycemic control. During phase III studies, sitagliptin was shown to cause toxicity to the pancreas, including pancreatitis. To date there is limited information available regarding its association with pancreatic carcinoma. Our goal was to qualitatively and quantitatively review available information in the AERS database in order to provide clinicians with a general understanding of the comparative occurrence of sitagliptin use and pancreatic carcinoma and any clinically relevant characteristics that may be useful in identifying patients at risk.
Nagel, Angela; Cipriano, Gabriela; Ahmed-Sarwar, Nabila; Van Manen, Robbert; and Brown, Jack, "Sitagliptin Associated Pancreatic Carcinoma: a Review of the FDA AERS Database" (2014). Pharmacy Faculty Publications. Paper 52.
Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.